In Brief: Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs: Begins shipments April 26 of the HIVAG-1 Monoclonal ELISA in vitro blood donor screening test, the second HIV-1 p24 antigen screening system to reach the market since the agency's August 1995 recommendation that blood banks screen for p24. Like Coulter's ELISA antigen screen that cleared FDA in March ("The Gray Sheet" March 18, p. 10), the Abbott test is intended to reduce the "window" period between HIV infection and detection. The Abbott test is priced competitively with the Coulter test, Abbott says. Prior to the Coulter test's approval, Abbott's polyclonal-based HIVAG-1 test for use in diagnosis and monitoring applications was the only HIV-1 antigen test system on the market...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.